Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
07 September 2018 Photo Stephen Collett
Mathematician makes popular contribution to science Prof Atangana
Prof Atangana is the first African under 40 years of age to be selected as African Academic of Science affiliated in Mathematics. He recently delivered his inaugural lecture and is pictured with Eelco Lukas, Director of the Institute for GroundwaterStudies at the UFS (middle) and Prof Hendri Kroukamp, Acting Vice-Rector: Academic
Prof Abdon Atangana, researcher in the Institute for Groundwater Studies at the University of the Free State (UFS), recently delivered his inaugural lecture on the topic: Understanding God’s Nature with Non-Local Operators.

His research interests are methods and applications of partial and ordinary differential equations, fractional differential equations, perturbation methods, asymptotic methods, iterative methods, and groundwater modelling. Prof Atangana is the founder of the fractional calculus with non-local and non-singular kernels popular in applied mathematics today. He has introduced more than 12 mathematical operators, most of which bear his name (such as the Atangana-Baleanu fractional integral).

He stated: “We will not stop until we change the classical view of doing mathematics. Mathematics is not a subject but a tool given to mankind by God to understand nature. One single mathematical operator cannot portray God’s nature accurately. Therefore the Atangana Baleanu was suggested.”

New weapons

Most physical problems can be expressed in terms of mathematical formulations called differential equations. According to him the differential equation’s aim is to analyse, understand, and predict the future of a physical problem. Prof Atangana introduced the Atangana-Baleanu fractional integral. This brought new weapons into applied mathematics to model complex real-world problems more accurately.

Prof Atangana explained: “The Atangana-Baleanu fractional derivative is able to describe real-world problems with different scales, or problems that change their properties during time and space for instance, the spread of cancer, the flow of water within heterogeneous aquifers, movement of pollution within fractured aquifers, and many others. This crossover behaviour is observed in many empirical systems.”

Sudden change

The Atangana-Baleanu fractional derivative is also able to describe physical or biological phenomena, such as a heart attack, the physiological progression from life to death, structural failure in an aeroplane, and many other physical occurrences with sudden change with no steady state.

The new differential and integral operators are nowadays in fashion and are being applied with great success in many fields to model complex natural phenomena. It is believed that the future of modelling complex real-world problems relies on these non-local operators.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept